Mode
Text Size
Log in / Sign up

Prefrontal rTMS or theta burst stimulation significantly improves response and remission in MDDRepetitive magnetic stimulation reduces symptoms for treatment resistant depression

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that prefrontal rTMS robustly improves response and remission in MDD without linear dose-response benefits.

This meta-analysis evaluated the efficacy of prefrontal repetitive transcranial magnetic stimulation (rTMS) or theta burst stimulation compared to sham for adults with Major Depressive Disorder (MDD) and treatment-resistant depression. The analysis included a total sample size of 1850 patients.

The primary finding was that active rTMS significantly reduced depressive symptoms compared to sham (Hedges' g = -1.056; 95% CI -1.407 to -0.704; p < 0.001). Secondary outcomes showed robust effects for both response (OR = 4.78; 95% CI 3.08-7.41) and remission (OR = 3.55; 95% CI 2.06-6.13). Notably, the analysis found no significant linear dose-response relationships regarding frequency, intensity, total pulses, session number, or treatment duration.

A limitation noted by the authors is high heterogeneity in depressive symptoms (I = 84.6%). Additionally, effect sizes were larger in single-blind versus double-blind trials (Q p < 0.001). Clinical evidence suggests that while prefrontal rTMS robustly increases response and remission probability, increasing dose or intensity does not provide a proportional linear benefit.

How this fits prior evidence

This meta-analysis addresses a gap in treatment options for MDD and treatment-resistant depression by providing high-certainty evidence for rTMS. It offers an alternative to transcranial direct current stimulation, which provides only modest and short-term relief in treatment-resistant depression. Additionally, it provides a different therapeutic pathway compared to second-generation antipsychotics or antidepressant-antipsychotic combinations used for MDD and psychotic depression.

Living with major depressive disorder can feel like an uphill battle, especially when standard treatments do not seem to work. For these individuals, finding a reliable way to manage symptoms is vital. A large review of clinical trials involving 1,850 adults found that prefrontal repetitive transcranial magnetic stimulation (rTMS) and theta burst stimulation significantly reduced depressive symptoms compared to a sham treatment.

The data showed robust results for both patient response and remission, which means patients were much more likely to see an improvement in their condition. However, the researchers found something interesting about how the treatment is delivered. They did not find that increasing the dose, intensity, or number of pulses led to a direct, linear increase in how well the treatment worked.

While the results for remission and response are considered high-certainty, it is important to note that there was significant variation in how depressive symptoms were measured across different studies. Because individual needs vary, patients should talk to their doctor to see if this specific type of magnetic stimulation is a right fit for their personal treatment plan.

What this means for you:
Magnetic brain stimulation significantly improves depression symptoms, regardless of the specific dose or intensity used.

Common questions

How effective is this magnetic stimulation for depression?

The study found that active rTMS significantly reduced depressive symptoms compared to a sham treatment. It also showed robust effects for both response and remission, meaning patients were much more likely to see an improvement in their condition than those who did not receive the active treatment.

Does a higher dose of the treatment make it work better?

The research found no significant linear dose-response relationships. This means that increasing factors like the intensity, frequency, total pulses, or number of sessions did not result in a proportional increase in how well the treatment worked for patients.

Who is this treatment intended for?

This treatment was studied in adults with major depressive disorder (MDD) and those specifically dealing with treatment-resistant depression. These are individuals who may not have seen success with standard medical approaches to managing their symptoms.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: Prefrontal repetitive transcranial magnetic stimulation (rTMS) is an established treatment for major depressive disorder (MDD), yet heterogeneity in stimulation protocols has led to debate regarding optimal parameters. Whether higher intensity, pulse dose, or session density translates into superior efficacy remains unclear. We conducted a sham-controlled meta-analysis to examine protocol-level moderators of antidepressant response. METHODS: PubMed, Web of Science, and CENTRAL were searched to January 2026. Randomized sham-controlled trials evaluating prefrontal rTMS or theta burst stimulation in adults with MDD or treatment-resistant depression (TRD) were included. Random-effects meta-analyses using restricted maximum likelihood estimation with Hartung-Knapp adjustment were performed. Meta-regressions examined dose-response relationships across frequency, intensity, total pulses, session number, and treatment duration. Risk of bias was assessed using ROB 2.0; certainty of evidence with GRADE. RESULTS: Thirty comparisons (N = 1850) were included. Active rTMS reduced depressive symptoms versus sham (Hedges' g = -1.056, 95% CI -1.407 to -0.704; p < 0.001), with high heterogeneity (I = 84.6%; 95% PI -2.42 to +0.31). Binary outcomes showed robust effects: response OR = 4.78 (95% CI 3.08-7.41; NNT = 2.9; I = 21.9%) and remission OR = 3.55 (95% CI 2.06-6.13; NNT = 4.4; I = 34.5%), both high-certainty by GRADE. Meta-regression identified no significant linear dose-response relationships. Effect sizes were larger in single-blind versus double-blind trials (Q p < 0.001). CONCLUSIONS: Prefrontal rTMS robustly increases response and remission probability in MDD. Greater dose or intensity does not confer proportional benefit linearly, suggesting dose-escalation strategies require reconsideration in favor of precision-oriented approaches.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.